GLUSA-K 750mg TABLET

Name & Strength of active Ingredient(s)
Each film-coated tablet contains Crystalline Glucosamine Sulphate Potassium Chloride 996 mg (equivalent to Glucosamine sulphate 750 mg).

Dosage Form
Film coated Tablet

Product Description
Oval pale yellow film-coated tablet embossed with "SPS" on one side and "S" and "12" with a breakline on the other side. Tablet size is approximately 9.5 mm x 19.5 mm x 8.1 mm.

Pharmacodynamics
Glucosamine has the following therapeutic activities:
1) Arthrotropic metabolic activity – by stimulating the anabolic metabolism of osteocartilageneous tissues via stimulation of the biosynthesis of the mucopolysaccharides (which are essential components of the cartilage groundsubstances) and of the bone mesenchymal tissues.
2) Lubricant activity – by increasing synovial fluid production and hence improve the synovial fluid viscosity.

Glucosamine is used in all forms of degenerative osteoarticular disease such as arthrosis and osteoarthritis (both subacute and chronic) with the following therapeutic effects: disappearance or reduction of articular pains, improvement of articular function, inhibition of regression of the degenerative process.

Pharmacokinetics
Glucosamine is highly absorbable in the sulphate form and the sulphate component appears to potentiate the therapeutic effect of glucosamine therapy.
When taken orally, about 90% of glucosamine sulphate is absorbed from the digestive tract and from there it is transported via the portal circulation to the liver. It appears that a significant fraction of the ingested glucosamine is catabolised by first-pass metabolism in the liver. About 10% of the oral administered dose is excreted in the urine and approximately 11 % is excreted in the faeces as unabsorbed drug. The elimination half-life of glucosamine incorporated into the plasma proteins is about 68 hours after oral administration.
Some uptake in the articular cartilage is seen in animal studies. Free glucosamine is not detectable in plasma.

Indication
Glusa-K 750mg Tablet is indicated as adjunctive therapy in osteoarthritis.

Recommended Dosage
Adult
2 tablets daily (1,500 mg per day) in single dose or 2 divided dose or as prescribed by the physician.
The recommended duration of therapy is 3 months and the treatment course may be repeated at interval of 2 months or according to medical prescription.
Tablets should be taken 15 minutes before each meal. Glucosamine can be used for long-term treatment but may cause some gastrointestinal disturbances. Patients with gastrointestinal problem may take the tablets after meals.

Mode of Administration
For oral administration.

Contraindication
Glucosamine is contraindicated in patients with known hypersensitivity to Glucosamine. As the active ingredient is obtained from seafood (shellfish), the product should not be given to patients who are allergic to shellfish.

Warning and Precautions
Glucosamine treats the underlying cause of osteoarthritis and the therapeutic effect can only be seen after 2-3 weeks. Therefore, it is advisable to take an analgesic/anti-inflammatory drug if required during the first 2-3 weeks of therapy with Glucosamine.
Glucosamine may cause insulin to work less effectively. Hence, diabetic patients should have their blood sugar checked regularly. Patients with peptic ulcers are advised to take Glucosamine with food. Caution should be taken when use in patients with severe hepatic and renal insufficiency.
Administration during the first three months of pregnancy must be avoided. Safety and effectiveness have not been established in children therefore children, should avoid using glucosamine A doctor should be consulted in order to exclude the presence of other joint conditions/disesases for which an alternative treatment should be considered.
The use of warfarin and glucosamine may cause an increase in INR value, potentiate anticoagulant effect and potentially increase the risk for bleeding. During concomitant treatment, closely monitor the prothrombin time (PT) or International Normalized Ratio (INR). Warfarin dosage adjustments may be required when glucosamine therapy is initiated or modified during concomitant treatment.

Interaction with Other Medicaments
Antidiabetic agent –Glucosamine may reduce oral antidiabetic agent effectiveness.Therefore, glucose level should be monitored when Glucosamine is administered concurrently with antidiabetic agent.
Warfarin – Glucosamine may alleviate International Normalized Ratio serum values and potentiation of anticoagulant effects.
The following anticancer drugs have a theoretical reduced effectiveness when used with glucosamine: Doxorubicin , Etoposide , Teniposide.

Pregnancy and Lactation
Available evidence is inconclusive or inadequate for used in pregnant or lactating mothers. Until more information is available, this product should only be used under medical supervision in lactating mothers and pregnancy if the potential benefits to the mother justifies the potential risk to the fetus. Administration during the first 3 months of pregnancy must be avoided.

Side Effects
Cardiovascular: Peripheral oedema, tachycardia were reported in a few patients following larger clinical trials investigating oral administration in osteoarthritis. Causal relationship has not been established.
Central nervous system: Drowsiness, headache, insomnia, somnolence have been observed rarely during therapy (less than 1%).
Gastrointestinal: Nausea, vomiting, diarrhoea, dyspepsia or epigastric pain, constipation, heartburn and anorexia have been described rarely during oral therapy with glucosamine.
Skin: Skin reactions such as erythema and pruritushave been reported with therapeutic administration of glucosamine.

Symptoms & Treatment of Overdose
Glucosamine sulphate has a long track of being safe. However, extremely high levels of Glucosamine sulphate (many times the daily dose) can cause gastric fluctuations such as soft stools, diarrhoea and nausea.

Storage Condition
Store in a cool dry place, below 30 °C. Protect from light.
Keep out of reach of children. *Jauhi daripada kanak-kanak.*

Shelf life
Please refer to outer label.

Packing and Pack Sizes
Aluminium-PVC blister strips packed in cardboard box consisting 5 x 10's, 10 x 10's or 50 x 10's.

Manufacturer:
SRIPRASIT PHARMA CO., LTD.
216 Moo 6, Suanluang, Krathum Baen, Samut Sakhon 74110, Thailand.

Rev : Oct 2018